Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatorenal syndrome.

Mónica Guevara1, Juan Rodés

  • 1Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, C/Villarroel 173, 08032 Barcelona, Spain. mguevara@clinic.ub.es

The International Journal of Biochemistry & Cell Biology
|September 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atypical Mal de Meleda in a Hispanic Patient.

Case reports in dermatological medicine·2023
Same author

Current treatment strategies for hepatorenal syndrome.

Clinical liver disease·2019
Same author

Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.

Journal of gastroenterology and hepatology·2019
Same author

Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.

Journal of hepatology·2018
Same author

The impact of cortisol in steatotic and non-steatotic liver surgery.

Journal of cellular and molecular medicine·2017
Same author

Effects of alfapump™ system on kidney and circulatory function in patients with cirrhosis and refractory ascites.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2017

Hepatorenal syndrome (HRS), a severe complication of cirrhosis, involves circulatory and renal dysfunction. Treatment with albumin and vasoconstrictors, or shunts, can reverse HRS and improve survival, potentially bridging patients to liver transplantation.

Area of Science:

  • Hepatology
  • Nephrology
  • Critical Care Medicine

Background:

  • Hepatorenal syndrome (HRS) is a serious complication in cirrhosis patients, impacting survival.
  • It affects approximately 8% of patients with ascites annually and signifies advanced disease.
  • Understanding HRS pathogenesis and effective treatments is crucial for patient outcomes.

Purpose of the Study:

  • To elucidate the pathogenesis of hepatorenal syndrome (HRS).
  • To review current and potential therapeutic strategies for HRS.
  • To assess the impact of treatments on patient survival and liver transplantation eligibility.

Main Methods:

  • Review of existing literature on hepatorenal syndrome.
  • Analysis of the pathophysiology involving splanchnic vasodilation and reduced cardiac output.

Related Experiment Videos

  • Evaluation of treatment modalities including albumin, vasoconstrictors, and transjugular intrahepatic portacaval shunt (TIPS).

    • Main Results:

    • HRS pathogenesis involves decreased effective arterial blood volume and intrarenal mechanisms.
    • Type 1 HRS has a poor prognosis (median survival < 2 weeks), while Type 2 shows steady functional impairment.
    • Simultaneous administration of albumin and vasoconstrictors can reverse HRS.
    • Long-term treatment or TIPS can improve survival and serve as a bridge to liver transplantation.

    Conclusions:

    • Hepatorenal syndrome is a critical determinant of survival in cirrhosis.
    • Effective management involves addressing circulatory dysfunction with albumin and vasoconstrictors.
    • Interventions like TIPS and liver transplantation offer improved survival prospects for HRS patients.